Core polypeptides of UsnRNPs are recognized by the sera of a subclass of rheumatic patients suffering from systemic lupus erythematosus (SLE). Autoantibodies against the UsnRNP-core polypeptides are detected in 10−30% of SLE patients, depending on the detection technique and source of antigen used [1]. Core polypeptides are found in UsnRNPs [1] and are highly conserved through evolution being found in both humans and yeast [2−5].

We focused on the Sm motifs of the UsnRNP-core polypeptides: Sm motif 1 (referred to as Motif-1) encompasses 32 amino acids and Sm motif 2 encompasses 14 amino acids [2–5]. Both motifs are conserved in all human UsnRNP core polypeptides B′, B, D1−3, E, F and G. Using Western blotting, it has been demonstrated that B′, B and D1−3 polypeptides are recognized by sera from SLE patients (SLE sera) [6]. However, E, F and G autoantibodies are rarely detected in SLE sera [7]. This is particularly surprising because human D1 and D3 polypeptides present lower homologies to the consensus sequence than E, F and G polypeptides [2−5]. Neither epitope mapping studies nor peptide assays have given clear autoimmune data on the region that contains the UsnRNP Sm motif 1 and Sm motif 2 [8−17]. Only truncated versions of Sm motifs were used. In previous studies, Rokeach et al. [10] used two fusion proteins: one containing a complete Sm motif 1 and the other containing a truncated version of the Sm motif 1 plus a complete Sm motif 2. Both gave negative results with Western blotting against 19 anti-(Sm) sera. Therefore, the techniques used may explain why not all the UsnRNP-core polypeptides have been detected with anti-(Sm) sera. In this regard, Brahms and colleagues [18] have recently shown that E, F and G proteins are recognized as a tri-polypeptide complex under native conditions, but are not recognized in their denatured states. Other authors have reported positive reactions for anti-(Sm) sera against truncated peptides of Sm motifs [8,11−13,16,17], thus indicating that this region probably contains an epitope that reacts with anti-(Sm) sera. As the Sm motifs have been clearly described from sequence comparisons [2,4,5], it is now possible to study and analyze one complete Sm motif. Sm motifs 1 and 2 are interesting regions as they are found both in yeast and human proteins. There is some degree of conservation between the different Sm motifs, but it is not evident whether they show similar cross-reactivity to antibodies obtained against one particular Sm motif. We focused our interest on Sm motif 1 of the yeast F protein [2,4,5], and obtained polyclonal antibodies against the Sm motif 1. Immunoaffinity purified polyclonal antibodies from immunized animals cross-reacted extensively with human B′, B, D1 and D3 Sm proteins. This indicates that the Sm motifs from the yeast F protein and human B′, B, D1 and D3 Sm polypeptides contain a common feature which is recognized by the polyclonal sera.

**MATERIALS AND METHODS**

**Patients and sera from normal donors**

Two-hundred and fourteen sera from human SLE patients were tested in this study. The SLE patients were selected according to American Rheumatism Association (ARA) classification criteria for SLE; 95 sera from healthy donors were obtained from the blood bank.

**Peptide choice and synthesis**

We selected a Sm motif 1 from the partially sequenced yeast F protein, taking into account the following: a yeast peptide should render a better antibody response in mammals; the Sm...
Fig. 1. Comparison of yeast and human Sm motifs. The amino acids in the black boxes represent fully conserved positions, whereas those in white boxes indicate sequences with 70–85% conservation. Sm motif 1 and Sm motif 2 are 32 and 14 amino acids long, respectively, according to the boxes. Black boxes represent fully conserved positions, whereas those in white represent positions with 70–85% conservation. Sm motif 1 is larger than the Sm motif 2 and contains more unchanged amino acids in the conserved region (Figs 1 and 2a); as the Sm motif 1 is not a clear or strong epitope recognized by anti-(Sm) sera, a Sm motif 1 from a non-typical Sm antigen was chosen, i.e. a Sm motif 1 different to those found in B, T and D polypeptides, as these proteins are highly reactive with anti-(Sm) sera. In conclusion, any one of the three E, F and G polypeptides would have been suitable for our purpose, and we finally chose the Sm motif 1 of the yeast F polypeptide because its chemical synthesis was easier than that of the other two.

The Sm motif 1 from the yeast F protein has a homology of 91% with the Sm motif 1 consensus sequence (Fig. 2a) and a homology of 68% with the Sm motif 1 of human F protein (counting unchanged amino acids and hydrophobic amino acids at the same position; Fig. 2b). The percentage homology of the selected yeast F peptide with the same region of each core protein is shown in Fig. 2b.

A second important factor is the purity of the peptide. Special care was taken using HPLC to obtain a peptide with a purity of >95%. The peptide was conjugated to keyhole limpet hemocyanin (KLH), which is a nonrelated protein that normally gives a low background in ELISA against rabbit and SLE sera (our unpublished results). One cysteine was added to the C-terminus of the peptide to allow coupling with KLH. A second conjugate containing Motif 1-BSA was also obtained to carry out ELISA assays with the immunized rabbit sera, thus monitoring the efficiency of immunization with Sm motif 1-KLH (named Motif 1-KLH).

Motif 1–peptide conjugate

Sm–peptide conjugate containing the Sm amino acid motif 1 of the putative yeast F protein (YRTGLVSTDNYFLNLQLEAEEFP), 22 amino-acids from the Sm motif 1 of the yeast F protein plus a cysteine added to the C-terminus) was obtained using solid-phase methods, such as C-terminal carboxamides on p-methylenhydrilamine resin using tert-butyloxy carbonyl (Boc) chemistry at the Department of Organic Chemistry of the University of Barcelona. An extra tyrosine residue (Y) was added to the N-terminus in order to increase the homology of the Sm motif 1 of the yeast F peptide with the Sm motif 1 of the human F peptide. After hydrofluoric acid (HF) cleavage and HPLC purification, the products were characterized by amino acid analysis and electrospray mass spectrometry. Coupling to KLH was carried out using the 3-maleimidobenzoyl-N-hydroxysuccinimide ester following Kitagawa and Aikawa [19]. Peptide-to-carrier molar ratios of 3517 to 1, were determined by amino acid analysis of the conjugates and the conjugate thus obtained was named Motif 1-KLH. A similar conjugate using BSA rather than KLH was also obtained using the same procedure.

Animal immunizations

Two New Zealand White rabbits, R328 and R329, were immunized with the Motif 1-KLH conjugate as follows: day 1, 150 μg in NaClIP/complete Freund adjuvant (NaClIP; NaCl 140 mm; K₂HPO₄, 20 mm) (1 : 1, v/v); subsequent immunizations were carried out with 100 μg in NaClIP/ incomplete Freund adjuvant (1 : 1, v/v) on days 15, 30 and 60. On day 67, blood was taken from the animals’ ears. Sera were obtained by
centrifugation of the blood and their titers were assayed using ELISA.

**Purification of human UsnRNPs and Western blotting**

Purification of human UsnRNPs from human extracts (HeLa cells) was carried out with anti-(trimethylguanosine) columns [20]. Further purification of the UsnRNPs using Mono Q FPLC columns gave purified U1snRNP [20]. Western blotting with purified human UsnRNPs was performed as described previously [21]. Two gel systems were used to resolve the U1snRNP proteins: 10% polyacrylamide/SDS/tricine gels [22] or 12.5% polyacrylamide/SDS/high-TEMED gels [23], depending on the purpose of the experiment (see Results). Western blotting with the peptide only was similarly performed by running 2 μg peptide-lane⁻¹ in 10% polyacrylamide/SDS/tricine gels [22] and transferring the peptide to 0.2 μm nitrocellulose membranes at 200 mA for 1 h in transfer buffer (Tris/HCl 25 mM pH 8.3, glycine 192 mM, 10% methanol). Blot immunostaining was performed with protein A–alkaline phosphatase and ECL (Amersham Life Science) Western detection reagents (chemoluminescence), following the manufacturer’s instructions.

**Immunoprecipitation**

Immunoprecipitation of the UsnRNPs from HeLa nuclear extracts was essentially performed as described previously [24] with some modifications: all incubation steps including binding of the polyclonal antibody to protein A–Sepharose and the UsnRNPs to the protein A–antibody matrix were performed overnight at 4 °C. HeLa nuclear extract samples were first incubated at 37 °C for 30 min, to improve the exposure of the epitopes to the antibodies, and then 50 μL of this extract was added to the protein A–antibody matrix to continue the immunoprecipitation.

**Purification of the antibodies using immunoaffinity columns**

The peptide containing the yeast Sm motif 1 was covalently bound to Sepharose using CNBr-activated beads, following the manufacturer’s instructions. Sera from both immunized rabbits were saturated to 50% with ammonium sulfate and centrifuged. The pellets, which contained the antibodies, were dissolved and dialyzed against NaCl/P, 300 (same as NaCl/P, but containing 300 mM NaCl) plus 0.5 mM PhCH₂SO₂F. After dialysis, the antibody solution was applied slowly to the peptide column (previously equilibrated with NaCl/P, 300/PhCH₂SO₂F). After washing with NaCl/P, 300/PhCH₂SO₂F (6 column vol.), the bound antibodies were eluted with 100 mM glycine/HCl pH 2.5, and the eluted fractions were immediately collected in one fraction-volume of 1 mL Tris pH 8, and mixed to change the pH. Protein fractions were dialyzed against NaCl/P/PhCH₂SO₂F and then assayed using ELISA plates with wells coated with Motif 1-BSA. Using this column we have been able to purify 1–2% of the IgG fraction.

**Anti-(Motif 1-KLH) ELISA**

ELISA wells (Maxisorp, NUNC) were coated with 50 μL of a solution of Motif 1-KLH conjugate in NaCl/P, (20 mM KH₂PO₄ pH 7.4, 140 mM NaCl, 0.02% NaN₃) at a concentration of 10 μg·mL⁻¹. The control wells were coated with the same amount of KLH alone. The plates were covered with a wipe and incubated overnight at room temperature in order to dry the wells. Next day the plates were dried for 1 h at 37 °C and then washed six times with NaCl/P, and saturated with 100 μL of NaCl/P/2% teleostean gelatin for 1 h at 37 °C. Then the plates were washed six times with NaCl/P, and 50 μL of the human sera diluted 1/400 in 2% teleostean gelatin/NaCl/P/T (NaCl/P, with 0.1% Tween 20) was added to each well (both the peptide–KLH and KLH alone wells) and then incubated for 90 min at 37 °C. The plates were washed six times with NaCl/P, and 50 μL of anti-(human specific IgG), (with minimal cross-reactivity to either IgM or IgA, as these antibodies were purified by loading to human IgM and IgA columns), conjugated to alkaline phosphatase and diluted 1/2000 in 2% teleostean gelatin/NaCl/P/T, was added to all the wells, which were then incubated for 1 h at room temperature. The plates were washed six times with NaCl/P, 80 μL of substrate solution (50 mM Na₂CO₃/NaHCO₃ pH 9.5, 2 mM MgCl₂ and 1 mg·mL⁻¹ p-nitro-phenyl-phosphate) was added to each well and the plates were read at 405/450 nm 30 min later. The value obtained against KLH only is the background of the assay and was subtracted from the values obtained against Motif 1-KLH conjugate (the present work contains already subtracted data; i.e. absorbance value of the serum vs. Motif 1-KLH conjugate – absorbance value of the serum vs. KLH only). Owing to the high ratio of conjugation (3500 : 1) 30% of the sera was also assayed in parallel with 10 μg KLH only, and similar absorbance values were obtained with 5 μg or 10 μg of KLH only. Absorbance values against KLH were low (the statistical evaluation of the data is shown in the legend to Fig. 1).

ELISA using rabbit sera was performed in a similar way, but using Motif 1-BSA to coat the wells (thus avoiding cross-reactivity with the carrier KLH) and with a specific anti-(rabbit) IgG.

**Competitive inhibition ELISA**

The ELISA wells (Maxisorp, NUNC) were prepared as described above but with 50 μL of the solution of Motif 1-KLH conjugate and NaCl/P, (20 mM KH₂PO₄ pH 7.4, 140 mM NaCl, 0.02% NaN₃), at a concentration of 5 μg·mL⁻¹, and incubated at room temperature. Sm motif 1 peptide was prepared in NaCl/P, at 300 ng·mL⁻¹. The sera were diluted 1/400 in 2% teleostean gelatin/NaCl/P, A 50-μL aliquot of the diluted sera was allowed to compete with 50 μL of the Motif 1-KLH conjugate solution at room temperature for 1 h in an assay tube. The control, which consisted of diluted serum without inhibitor, was prepared by adding 50 μL of the diluted incubated sera to 50 μL of NaCl/P, under the same conditions as those used for the competition samples. The plates were then washed three times with NaCl/P/T and saturated with 100 μL of NaCl/P/2% teleostean gelatin for 30 min at room temperature. The plates were then washed three times with NaCl/P, and the competition mixture (50 μL of diluted serum plus 50 μL of peptide solution) and control incubation (50 μL of diluted serum plus 50 μL of NaCl/P) were added to the corresponding wells and the plates were incubated for 1 h at 37 °C. The plates were washed three times in NaCl/P/T and 50 μL of specific anti-(human) IgG (with minimal cross-reactivity to IgM, IgA conjugated to alkaline phosphatase, diluted 1/4000 in 2% teleostean gelatin/NaCl/P/T) was added to the wells, which were then incubated for 90 min at room temperature. The plates were washed three times with NaCl/P/T and 80 μL of substrate solution (50 mM Na₂CO₃/NaHCO₃ pH 9.5, 2 mM MgCl₂ and 1 mg·mL⁻¹ p-nitro-phenyl-phosphate) was added. Thirty minutes later the plates were read at 405/450 nm. The inhibition observed in the ELISAs is shown as the percentage reduction of the absorbance at 405/450 nm in the competed wells with respect to the control.
RESULTS AND DISCUSSION

Antibodies obtained in rabbits against the yeast Sm motif 1 immunoprecipitated UsnRNPs from HeLa nuclear extracts

Two rabbits were immunized with the Motif 1-KLH conjugate. Sera from both animals showed titers higher than 1/5000 in ELISAs coated with the Motif 1-BSA conjugate, whereas the corresponding nonimmune sera did not react with the Motif 1-BSA conjugate. The immunoreaction of the sera from immunized animals with the Motif 1-BSA conjugate was inhibited in competition ELISAs with increasing concentrations of free peptide (results not shown). To show that the animals were not rendering an immune response to the adjuvants, two other rabbits were immunized with KLH only (same protein quantity and same immunization protocol). Any sera from the two latter rabbits showed reactivity with the Sm motif 1 peptide (not shown).

Both sera were studied in immunoprecipitation assays in order to see whether they were able to bind to native UsnRNPs from human extracts. Figure 3 shows that serum R328 immunoprecipitated native UsnRNPs (Fig. 3, lane 1), whereas the nonimmune serum from the same animal did not (Fig. 3, lane 2). Although serum from rabbit R329 has the same titer as serum R328, R329 failed to immunoprecipitate native UsnRNPs (Fig. 3, lane 3). Lane 4 in Fig. 3 shows a positive control of the immunoprecipitation assay with serum R328 that correspond to small ribosomal RNAs (Fig. 3, lane 1). These additional bands were not studied further, as they were very faint, whereas UsnRNAs were clearly still present in immunoprecipitations performed using a smaller amount of nuclear extract (10 μL instead of the customary 50 μL; data not shown). Immunoprecipitation with 50 μL was selected as it allowed better visualization using silver staining. This experiment gave information about which UsnRNPs was immunoprecipitated by the sera but did not indicate which UsnRNP polypeptide is recognized during the immunoprecipitation assay. To answer this question we performed assays with denatured polypeptides.

Antibodies obtained in rabbits against the yeast Sm motif 1 recognized Sm polypeptides from human UsnRNPs on Western blotting

The reactivity of both R328 and R329 sera against denatured human U1snRNP polypeptides was assayed using Western blotting. As the polyacrilamide gel system used (tricine-based gel, 12.5%) did not separate the three bands D1, D2 and D3 (see below), we refer to the section of the gel containing D1±3 as the D1±3 region. Figure 4 shows that sera recognized human B’, B polypeptides and D1±3 region (Fig. 4, lanes 1 and 2), whereas the corresponding nonimmune serum of each animal did not (Fig. 4, lane 3 for R329 nonimmune serum and lane 4 for R328 nonimmune serum). In this assay, serum R329 showed less immunoreactivity to the D1±3 region than serum R328. Detection of the 70-kDa band in lane 1 with serum R328 is discussed below. As B’, B and D1±3 polypeptides contain the Sm motif 1, it may be concluded that the antibodies against the yeast Sm motif 1 cross-react with the human Sm B’, B polypeptides and the D1±3 region, presumably by recognizing the Sm motif 1 of all these polypeptides. Immunorecognition of E, F and G polypeptides was not obtained (Fig. 4 lanes 1 and 2); this is discussed further below. Interesting, R329 serum did not recognize native UsnRNPs (Fig. 3 lane 3) but did recognize denatured Sm polypeptides using Western blotting (Fig. 4 lane 2). This observation allows us to suggest that the denatured epitopes detected by R329 serum on Western blotting may be not accessible or hidden to the R329 polyclonal antibodies when native UsnRNPs are used as an antigen source, i.e. in immunoprecipitation assays. As R329 serum

\[ \text{RESULTS AND DISCUSSION} \]

**Antibodies obtained in rabbits against the yeast Sm motif 1 immunoprecipitated UsnRNPs from HeLa nuclear extracts**

Two rabbits were immunized with the Motif 1-KLH conjugate. Sera from both animals showed titers higher than 1/5000 in ELISAs coated with the Motif 1-BSA conjugate, whereas the corresponding nonimmune sera did not react with the Motif 1-BSA conjugate. The immunoreaction of the sera from immunized animals with the Motif 1-BSA conjugate was inhibited in competition ELISAs with increasing concentrations of free peptide (results not shown). To show that the animals were not rendering an immune response to the adjuvants, two other rabbits were immunized with KLH only (same protein quantity and same immunization protocol). Any sera from the two latter rabbits showed reactivity with the Sm motif 1 peptide (not shown).

Both sera were studied in immunoprecipitation assays in order to see whether they were able to bind to native UsnRNPs from human extracts. Figure 3 shows that serum R328 immunoprecipitated native UsnRNPs (Fig. 3, lane 1), whereas the nonimmune serum from the same animal did not (Fig. 3, lane 2). Although serum from rabbit R329 has the same titer as serum R328, R329 failed to immunoprecipitate native UsnRNPs (Fig. 3, lane 3). Lane 4 in Fig. 3 shows a positive control of the immunoprecipitation assay with serum R328 that correspond to small ribosomal RNAs (Fig. 3, lane 1). These additional bands were not studied further, as they were very faint, whereas UsnRNAs were clearly still present in immunoprecipitations performed using a smaller amount of nuclear extract (10 μL instead of the customary 50 μL; data not shown). Immunoprecipitation with 50 μL was selected as it allowed better visualization using silver staining. This experiment gave information about which UsnRNPs was immunoprecipitated by the sera but did not indicate which UsnRNP polypeptide is recognized during the immunoprecipitation assay. To answer this question we performed assays with denatured polypeptides.

**Antibodies obtained in rabbits against the yeast Sm motif 1 recognized Sm polypeptides from human UsnRNPs on Western blotting**

The reactivity of both R328 and R329 sera against denatured human U1snRNP polypeptides was assayed using Western blotting. As the polyacrilamide gel system used (tricine-based gel, 12.5%) did not separate the three bands D1, D2 and D3 (see below), we refer to the section of the gel containing D1±3 as the D1±3 region. Figure 4 shows that sera recognized human B’, B polypeptides and D1±3 region (Fig. 4, lanes 1 and 2), whereas the corresponding nonimmune serum of each animal did not (Fig. 4, lane 3 for R329 nonimmune serum and lane 4 for R328 nonimmune serum). In this assay, serum R329 showed less immunoreactivity to the D1±3 region than serum R328. Detection of the 70-kDa band in lane 1 with serum R328 is discussed below. As B’, B and D1±3 polypeptides contain the Sm motif 1, it may be concluded that the antibodies against the yeast Sm motif 1 cross-react with the human Sm B’, B polypeptides and the D1±3 region, presumably by recognizing the Sm motif 1 of all these polypeptides. Immunorecognition of E, F and G polypeptides was not obtained (Fig. 4 lanes 1 and 2); this is discussed further below. Interesting, R329 serum did not recognize native UsnRNPs (Fig. 3 lane 3) but did recognize denatured Sm polypeptides using Western blotting (Fig. 4 lane 2). This observation allows us to suggest that the denatured epitopes detected by R329 serum on Western blotting may be not accessible or hidden to the R329 polyclonal antibodies when native UsnRNPs are used as an antigen source, i.e. in immunoprecipitation assays. As R329 serum

Fig. 3. Immunoprecipitation of human UsnRNPs with antisera to the yeast peptide containing the Sm motif 1. RNAs extracted from the pellets after immunoprecipitation with protein A-Sepharose. The RNAs were electrophoresed in a 10% polyacrilamide/urea gel and stained with silver as described previously [20]. Lane 1, immunoprecipitated with serum R328; lane 2, immunoprecipitated with the same amount of nonimmune serum R328; lane 3, immunoprecipitated with serum R329; lane 4, immunoprecipitated with anti-(trimethylguanosine) serum (R331) obtained in rabbit [21a]; and lane 5, immunoprecipitated with the same amount of nonimmune serum R329 as in lane 3.

Fig. 4. Western blot of Sm polypeptides from human U1snRNP stained with crude sera from rabbits immunized with the yeast Sm motif 1 peptide. Lane 1, immunodetection with serum R328 (diluted 1/100); lane 2, immunodetection with serum R329 (diluted 1/100); lane 3, immunodetection with the nonimmune serum R329 (diluted 1/100); and lane 4, immunodetection with the nonimmune serum R328 (diluted 1/100). Molecular weight of the polypeptides: 70 kDa; B’, 29 kDa; B, 28 kDa; D1, 16 kDa; D2, 16.5 kDa; D3, 18 kDa; E, 12 kDa; F, 11 kDa; G, 9 kDa. The gel system used was tricine-Gly/SDS polyacrilamide (10%) mini-gel (5 cm long). The front of the gel was run for less time in order to have polypeptides E, F and G in the middle of the gel.
polypeptides: D1, D2 and D3. As this is the first report to also use elution of the immunoreactivity with the free Sm peptide. Immunoaffinity column, and were also retained after the antibodies from serum R329 bound specifically to the immunoaffinity-purified antibody did not (Fig. 5 lane 3). Thus, Western blotting (Fig. 5, lane 2), whereas a nonrelated and motif 1 peptide (transferred alone to a nitrocellulose sheet) by purification of the R328 serum.

In this paper, we show the results obtained with the R329 serum antibodies specifically recognized the peptide (data not shown). In order to better discern whether the immunorecognition of the polypeptides from human UsnRNP on Western blotting failed in the immunoprecipitation assays we further purified this sera by affinity columns in order to confirm the results seen in Western blotting.

Immunoaffinity-purified antibodies from serum R329 recognized both the yeast Sm motif 1 peptide and the Sm polypeptides from human UsnRNPs on Western blotting

In order to better discern whether the immunorecognition of the B', B polypeptides and the D1–3 region by the rabbit sera (shown in Fig. 4) is due to the binding of antibodies to the Sm motif 1 of each polypeptide, both sera were purified through an immunoaffinity column with the convalently bound peptide. Both sera bound to the peptide column, indicating that the polyclonal antibodies specifically recognized the peptide (data not shown). In this paper, we show the results obtained with the R329 serum as introduced before, but similar results were obtained with the R328 serum.

Immunoaffinity-purified antibodies recognized the yeast Sm motif 1 peptide (transferred alone to a nitrocellulose sheet) by Western blotting (Fig. 5, lane 2), whereas a nonrelated and immunoaffinity-purified antibody did not (Fig. 5 lane 3). Thus, the antibodies from serum R329 bound specifically to the peptide immunoaffinity column, and were also retained after elution of the immunoactivity with the free Sm peptide.

In order to better determine which polypeptides from the D1–3 region are recognized by the sera, we used Western blotting after running UsnRNP proteins in high-TEMED/SDS polyacrilamide gels, which separate the D1–3 region into three polypeptides: D1, D2 and D3. As this is the first report to also use tricine-Gly-based gels to separate UsnRNP proteins, Fig. 6A (tricine-based gel) and Fig. 6B (high-TEMED-based gel) show a comparison of both systems. These figures show that tricine-based gels do not resolve the D1–3 region as well as the high-TEMED-based gels. Nevertheless, the tricine-based gels gave good resolution of the B', B, E and F/G polypeptides. Using these

Fig. 5. Western blot of the yeast Sm motif 1 peptide alone with the immunoaffinity-purified antibodies from rabbit R329. The peptide alone was blotted onto nitrocellulose sheets as described in the Materials and methods. Lane 1, blotted peptide stained with Amido Black; lane 2, blotted peptide immunostained with the immunoaffinity-purified R329 antibody; lane 3, peptide immunostained with a nonrelated immunoaffinity-purified antibody. This nonrelated immunoaffinity-purified antibody was a rabbit polyclonal anti-(m3G) (antinucleoside) purified through a m3G-affinity column [19]. Lanes 2 and 3 were incubated with the same amount of immunoaffinity-purified antibody. The gel system used was tricine-Gly/SDS polyacrilamide (10%) mini-gel (5 cm long). The front of the gel was run for less time in order to have the peptide in the middle of the gel.

Immunoaffinity-purified antibodies from serum R329 recognized both the yeast Sm motif 1 peptide and the Sm polypeptides from human UsnRNPs. Lane 4, human serum from a healthy donor (diluted 1/500); lane 2, anti-RNP/Sm serum from a MCTD (mixed connective tissue disease) patient (diluted 1/500); lane 3, U1snRNPs proteins immunostained with a nonrelated immunoaffinity-purified antibody; lane 4, U1snRNPs proteins immunostained with the immunoaffinity-purified R329 antibodies. This nonrelated immunoaffinity-purified antibody (used in lane 3) was a rabbit polyclonal anti-(m3G) (antinucleoside) purified through a m3G-affinity column [20]. Lanes 3 and 4 were incubated with the same amount of antibody. (D) U1snRNPs proteins were overloaded (24 μg; lane 4) on a tricine-Gly/SDS polyacrilamide gel (10%) mini-gel (5 cm long), blotted onto a nitrocellulose membrane and immunostained: lane 1, U1snRNPs proteins immunostained with the immunoaffinity-purified R329 antibody; lane 2, U1snRNPs proteins immunostained with a nonrelated immunoaffinity-purified antibody. This nonrelated immunoaffinity-purified antibody was a rabbit polyclonal anti-(m3G) (antinucleoside) purified through a m3G-affinity column [20]. Lanes 1 and 2 were incubated with the same amount of antibodies. The autoradiography exposure time was higher than usual in Fig. 6D (4.5 times higher) in order to better establish positive or negative immunostaining of polypeptides E, F and G. A mini-gel was used in the experiment shown in Fig. 6D in order to save material and have a higher amount of polypeptides E, F and G on the gel. The front of the gel showed in Fig. 6D was run for less time in order to have polypeptides E, F and G in the middle of the gel. Molecular weight of the polypeptides: 70 kDa; B', 29 kDa; B, 28 kDa: D1, 16 kDa; D2, 16.5 kDa; D3, 18 kDa; E, 12 kDa; F, 11 kDa; G, 9 kDa.

Fig. 6. Western blot of proteins extracted from human U1snRNP immunostained with immunoaffinity-purified R329 antibody. (A) U1snRNPs proteins resolved in a long (15 cm) tricine-Gly/SDS polyacrilamide gel (10%) and stained with Coomassie blue. (B) U1snRNPs proteins resolved on a long (15 cm) high-TEMED/SDS polyacrilamide gel (12.5%) and stained with Coomassie blue. (C) U1snRNPs proteins (8 μg; lane 3) resolved in a long (15 cm) high-TEMED/SDS polyacrilamide gel (12.5%), blotted onto a nitrocellulose membrane and immunostained with: lane 1, human serum from a healthy donor (diluted 1/500); lane 2, anti-RNP/Sm serum from a MCTD (mixed connective tissue disease) patient (diluted 1/500); lane 3, U1snRNPs proteins immunostained with a nonrelated immunoaffinity-purified antibody; lane 4, U1snRNPs proteins immunostained with the immunoaffinity-purified R329 antibodies. The nonrelated immunoaffinity-purified antibody (used in lane 3) was a rabbit polyclonal anti-(m3G) (antinucleoside) purified through a m3G-affinity column [20]. Lanes 3 and 4 were incubated with the same amount of antibody. (D) U1snRNPs proteins were overloaded (24 μg; lane 4) on a tricine-Gly/SDS polyacrilamide gel (10%) mini-gel (5 cm long), blotted onto a nitrocellulose membrane and immunostained: lane 1, U1snRNPs proteins immunostained with the immunoaffinity-purified R329 antibody; lane 2, U1snRNPs proteins immunostained with a nonrelated immunoaffinity-purified antibody. This nonrelated immunoaffinity-purified antibody was a rabbit polyclonal anti-(m3G) (antinucleoside) purified through a m3G-affinity column [20]. Lanes 1 and 2 were incubated with the same amount of antibodies. The autoradiography exposure time was higher than usual in Fig. 6D (4.5 times higher) in order to better establish positive or negative immunostaining of polypeptides E, F and G.
Fig. 7. Cross-reactivity of human SLE sera with the yeast Sm motif 1 peptide. ELISAs were performed as described in the Materials and methods. Statistical treatment of the data was carried out with Statview II program (ANOVA). Number of sera: healthy \( n = 95 \); SLE \( n = 214 \). *A significant reaction of the SLE sera with the peptide \( P < 0.05 \), as compared with data from healthy sera. Column A shows the results with all the SLE sera: 0.3 ± 0.15 (mean ± SD). Column B shows the data with healthy sera: 0.06 ± 0.06 (mean ± SD). The definition of positive sera by ELISA was as follows: detection threshold = 2 × mean ± 2 × SD of the values obtained with the healthy donor sera. This definition indicated that 70% of the sera were positive, and only these are shown in column C: \( 0.37 ± 0.12 \) (mean ± SD).

results we selected the gel system depending on the purpose of the experiment: when the \( D_{1-3} \) region was to be discriminated, high-TEMED-based gels were used; and when low molecular weight polypeptides were to be assayed (e.g. the E, F and G polypeptides or the free yeast peptide) tricine-based gels were used.

Purified R329 antibodies were again used with denatured human U1snRNP analyzed by Western blotting with a high-TEMED gel. Figure 6C shows that the purified antibodies recognized the Sm polypeptides \( \beta' \), B, D1 and D3 (Fig. 6C, lane 4), whereas a nonrelated immunoaffinity-purified antibody did not (Fig. 6C lane 3). The \( D_2 \) polypeptide was not detected using the immunoaffinity-purified antibodies. Similar results were obtained with purified R328 antibodies (not shown).

Therefore, we conclude that the purified antibody cross-reacts with the Sm motif 1 of the human Sm polypeptides \( \beta' \), B, D1 and D3. Similar results were obtained previously with several sera from SLE patients, which contained antibodies that cross-reacted with \( \beta' \), B, D1 and D3 polypeptides but not with \( D_2 \) polypeptide [23]; this was further confirmed using immunoaffinity-purified antibodies [23].

The immunoaffinity-purified antibodies did not stain E, F and G polypeptides even after increasing the amount of protein loaded onto the gel and using tricine-based gels (Fig. 6D, lane 1). The crude sera were also unable to stain E, F and G polypeptides (Fig. 4 lanes 1 and 2). This was not expected, as the peptide used in the immunizations has a higher homology to the polypeptides (Fig. 4 lanes 1 and 2). This was not expected, as the peptide used in the immunizations has a higher homology to the polypeptides (Fig. 4 lanes 1 and 2).

Additional care was taken to ensure that E, F and G polypeptides were present in our blots. After transfer, nitrocellulose sheets were stained with Ponceau S, Amido Black and Coomassie blue; in all the experiments, the staining of the blots indicated that both E, F and G were perfectly blotted and that the amount of polypeptides blotted was large enough to be immunodetected. Other membranes were also used to perform the transfer, such as poly(vinylidene difluoride) (PVDF) membranes (e.g. Immobilon-P and Immobilon-B™), which are particularly good at retaining low molecular weight polypeptides or small peptides. Using PVDF membranes the results obtained were similar to those shown in Fig. 4 (data not shown). The immunostaining method was also reduced as much as possible (1 h) but no staining of E, F or G was obtained. All these control experiments indicated that there is no adverse event during transfer and immunostaining that could explain the failure to detect E, F and G polypeptides. Two other explanations are suggested to explain why E, F and G are not immunodetected.

Post-translational modifications may play an important role in the immunorecognition of \( \beta' \), B, and D1 polypeptides by anti-(Sm) sera [16,25]. The Sm motif 1 in human E, F and G polypeptides could be post-translationally modified, and these modifications may disturb immunorecognition by our purified antibodies. Alternatively, protein folding may play an important role in immunorecognition of \( \beta' \), B, and D1 polypeptides by anti-(Sm) sera [16,25].

Brahms et al. [18] described a major SLE autoantibody class that recognizes native E–F–G complexes, but not E, F and G denatured polypeptides (e.g. Western blotting). Brahms et al. suggested the existence of an important conformational epitope in E–F–G complexes, which is only detected in the complex when in the native form.

The antibodies studied here may require an epitope with some type of protein folding not present in E, F and G polypeptides. With this reasoning we suggest that the conformation of the Sm motif 1 on the yeast peptide is more similar to that of the homologous region in human \( \beta' \), B, D1 and D3 proteins, but is apparently different from the corresponding regions of D2, E, F and G proteins.

Because of the high amount of protein loaded onto the gel (24 μg-lane\(^{-1}\)), the immunoaffinity-purified antibodies begin to stain the 70 kDa polypeptide nonspecifically (compare lanes 1 and 2 in Fig. 6D), this polypeptide is also recognized by the nonspecific serum; this nonrelated immunoaffinity-purified antibody was a rabbit polyclonal anti-(m3G), then an antinucleoside antibody, purified through a m3G-affinity column [20]. Further 70 kDa staining was not seen when the amount of
protein loaded onto the gel was reduced to 8 \( \mu \)g/lane\(^{-1}\) (Fig. 6C, lane 4). Nevertheless, it is not clear whether the 70 kDa staining in Fig. 4 lane 1 by R328 crude sera is a secondary immunoreaction of the animal, e.g. epitope spreading, and this is currently being studied.

Interestingly, in human Sm polypeptides Sm motif 1 does not seem to be equally accessible to all antibodies. Comparing lane 1 with lane 4 in Fig. 3 shows that the amount of immunoprecipitated U1, U2, U4 and U5 snRNAs is very similar (lane 1), whereas the total amount of U1snRNA in the sample is higher [note the amount of U1snRNA in lane 4, when anti-(trimethylguanosine) were used]. This may indicate that in native U1snRNP the Sm motif 1 is more hidden or less accessible to the anti-(Sm motif 1) than in the other UsnRNP.

Finally we conclude that the Sm motifs 1 of the UsnRNP contain a common feature that allows cross-reaction of antibodies between yeast and human Sm motifs 1.

**Yeast Sm motif 1 peptide is specifically recognized by a SLE antibody**

Our data indicate that antibodies raised against the yeast Sm motif 1 peptide cross-react with human Sm polypeptides. We were also interested in knowing whether a reversed experiment would be also successful, i.e. whether antibodies raised to human Sm motifs might cross-react with yeast Sm polypeptides. As a first approach, we tested a collection of SLE sera. The presence of anti-(Sm motif 1) that cross-reacted with yeast peptide containing the Sm motif 1 was assayed using a 214 SLE sera collection classified according to ARA criteria, and with 95 healthy donor sera. Figure 7 shows that 70% of the sera (150/214) presented statistically significant cross-reaction to the yeast Sm motif 1 peptide \((P < 0.05)\) when compared with data obtained using healthy sera (asterisk in Fig. 7 and its legend). The specificity of the reaction of the positive sera antibodies with the peptide was established by competitive inhibition: 22 sera from Fig. 7 were selected with absorbance units ranging between 0.25 and 0.5. Table 1 shows that the reaction of the sera to the Motif 1-KLH conjugate was inhibited when the free peptide was added to the assay, thus indicating that the antibody reaction is specific. Many sera from Table 1 were tested with different concentrations of the free competitor, and in all cases a higher level of inhibition was obtained when the concentration increased. Table 1 shows the levels of inhibition obtained at a free peptide concentration of 300 ng. The sera from Table 1 with an inhibition of < 50% with 300 ng of free peptide gave higher inhibition values when the concentration of the free peptide increased. This may represent affinity or quantitative differences in the antibodies. The assay did not determine whether this antibody specificity is an autoantibody (we intend to study this subject further using human peptides), but the results shown in Figs 3–6 indicated that antibodies to the yeast Sm motif 1 cross-reacted with human Sm polypeptides. Therefore, the antibodies found in SLE might recognize human Sm motifs. We randomly selected 30 sera from the positive population, i.e. sera that reacted with the yeast Sm motif 1 peptide, and in all of them we detected anti-(Sm) autoantibodies, i.e. antibodies that reacted with blotted human B\(^{2}\), B and D\(_{1-3}\) polypeptides (not shown). We may therefore presume that the sera which cross-reacted with the yeast Sm motif 1 peptide probably contain anti-(Sm) autoantibodies.

Taken together, these results allow us to suggest a hypothesis in which a Sm Motif 1-like protein, e.g. from an external agent, could initiate an immune reaction with the subsequent synthesis of antibodies that would cross-react with the host Sm polypeptides by a process of mimicry, and thus generate an autoimmune disorder. We are currently performing longer immunizations using more rabbits in order to answer this question.

**ACKNOWLEDGEMENTS**

We thank X. Jimenez for technical assistance, and all members of the M. Bach-Elias’ group for their comments about the manuscript. This work was supported by PGC grant no. PB92-0004 and PETRI no. 94-0186. R.B. Cicarelli was the recipient of a fellowship from CAPES and Spanish MEC; D. Bahia was the recipient first of a MUCIS fellowship and later of a CNPq fellowship. A. Khaouja was recipient of a fellowship from the Moroccan government. We also thank Marti Cullell for revising this manuscript.

**REFERENCES**


4. Seraphin, B. (1995) Sm and Sm-like proteins belong to a large family: identification of proteins of the U6 as well as the U1, U2, U4 and U5 snRNPs. EMBO J. 14, 2089–2098.


